Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracy...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1271420/full |
| _version_ | 1797594925962887168 |
|---|---|
| author | Weiwei Zeng Yuning Luo Dali Gan Yaofeng Zhang Huan Deng Guohui Liu |
| author_facet | Weiwei Zeng Yuning Luo Dali Gan Yaofeng Zhang Huan Deng Guohui Liu |
| author_sort | Weiwei Zeng |
| collection | DOAJ |
| description | Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracycline chemotherapy, has better efficacy in patients with metastatic TNBC (mTNBC). DOX in anthracycline-based chemotherapy regimens have higher response rates. Nano-drug delivery systems possess unique targeting and ability of co-load, deliver and release chemotherapeutic drugs, active gene fragments and immune enhancing factors to effectively inhibit or kill tumor cells. Therefore, advances in nano-drug delivery systems for DOX therapy have attracted a considerable amount of attention from researchers. In this article, we have reviewed the progress of nano-drug delivery systems (e.g., Nanoparticles, Liposomes, Micelles, Nanogels, Dendrimers, Exosomes, etc.) applied to DOX in the treatment of TNBC. We also summarize the current progress of clinical trials of DOX combined with immune checkpoint inhibitors (ICIS) for the treatment of TNBC. The merits, demerits and future development of nanomedicine delivery systems in the treatment of TNBC are also envisioned, with the aim of providing a new class of safe and efficient thoughts for the treatment of TNBC. |
| first_indexed | 2024-03-11T02:29:36Z |
| format | Article |
| id | doaj.art-45cbb6a9c9884a3b8d182fa603a7fb95 |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-03-11T02:29:36Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-45cbb6a9c9884a3b8d182fa603a7fb952023-11-18T10:17:35ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852023-11-011110.3389/fbioe.2023.12714201271420Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancerWeiwei Zeng0Yuning Luo1Dali Gan2Yaofeng Zhang3Huan Deng4Guohui Liu5Department of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, ChinaDepartment of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, ChinaDepartment of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, ChinaDepartment of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, ChinaDepartment of Pharmacy, Shenzhen Longgang Second People’s Hospital, Shenzhen, Guangdong, ChinaShenzhen Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, ChinaTriple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracycline chemotherapy, has better efficacy in patients with metastatic TNBC (mTNBC). DOX in anthracycline-based chemotherapy regimens have higher response rates. Nano-drug delivery systems possess unique targeting and ability of co-load, deliver and release chemotherapeutic drugs, active gene fragments and immune enhancing factors to effectively inhibit or kill tumor cells. Therefore, advances in nano-drug delivery systems for DOX therapy have attracted a considerable amount of attention from researchers. In this article, we have reviewed the progress of nano-drug delivery systems (e.g., Nanoparticles, Liposomes, Micelles, Nanogels, Dendrimers, Exosomes, etc.) applied to DOX in the treatment of TNBC. We also summarize the current progress of clinical trials of DOX combined with immune checkpoint inhibitors (ICIS) for the treatment of TNBC. The merits, demerits and future development of nanomedicine delivery systems in the treatment of TNBC are also envisioned, with the aim of providing a new class of safe and efficient thoughts for the treatment of TNBC.https://www.frontiersin.org/articles/10.3389/fbioe.2023.1271420/fulldoxorubicinnanocarrierstriple negative breast cancerdrug deliveryclinical |
| spellingShingle | Weiwei Zeng Yuning Luo Dali Gan Yaofeng Zhang Huan Deng Guohui Liu Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer Frontiers in Bioengineering and Biotechnology doxorubicin nanocarriers triple negative breast cancer drug delivery clinical |
| title | Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer |
| title_full | Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer |
| title_fullStr | Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer |
| title_full_unstemmed | Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer |
| title_short | Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer |
| title_sort | advances in doxorubicin based nano drug delivery system in triple negative breast cancer |
| topic | doxorubicin nanocarriers triple negative breast cancer drug delivery clinical |
| url | https://www.frontiersin.org/articles/10.3389/fbioe.2023.1271420/full |
| work_keys_str_mv | AT weiweizeng advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer AT yuningluo advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer AT daligan advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer AT yaofengzhang advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer AT huandeng advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer AT guohuiliu advancesindoxorubicinbasednanodrugdeliverysystemintriplenegativebreastcancer |